Install
Pharmaphorum is an online publication on a mission to educate, inform, engage, and connect pharmaceutical industry leaders and to equip them to thrive in healthcare’s evolving digital future. Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in
- 1,023articles · 365d
- 2+ day agolatest article
- Sep 15, 2025earliest in window
- 70%with images
- 363avg words
- HTH 785
- HW 694
- health 508
- economy business and finance 336
- BI 281
- FIB 154
- science and technology 143
- SCT 61
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Data backs Vertanical's cannabis therapy for back pain
11+ mon, 1+ week ago (510+ words) The results of a phase 3 trial of Vertanical's cannabis-derived therapy VER-01 for chronic lower back pain have been published, and bode well for the ongoing reviews of marketing applications for the drug. Published in the journal Nature Medicine, the results…...
Tonix launches its new fibromyalgia drug in US
9+ mon, 2+ week ago (636+ words) Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 years. Tonmya (cyclobenzaprine HCl) is a new…...
LSX2026: Non-opioid pain relief and pharma positivity, with Mike Cooke
5+ mon, 3+ hour ago (155+ words) In our penultimate video from this year’s LSX World Congress, web editor Nicole Raleigh spoke with Mike Cooke, CEO of AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a…...
AbbVie charts a new course for CGRPs in menstrual migraine
2+ day, 8+ hour ago (489+ words) AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine, which is severe and tends to resist current treatments. Qulipta (atogepant) has already become a blockbuster treatment after being…...